Want to see AU:RCE full AI Analyst Report?
Top Page
Recce Pharmaceuticals Ltd.
(Sydney:RCE)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.30
â–¼(-21.32% Downside)
Action:Reiterated
Date:09/06/26
The score is primarily held down by weak financial performance (negative equity, ongoing losses and cash burn, and a latest-period revenue drop to zero). Technicals add additional pressure with the stock trading below longer-term moving averages and a negative MACD. Valuation does not provide support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Anti-infective pipeline targets resistant pathogens
Targeting drug-resistant bacterial infections addresses a substantial unmet medical need and gives the pipeline a clear clinical rationale. If development succeeds, these candidates could serve indications where existing antibiotics are less effective, supporting differentiated commercial potential over the next several years.
Negative Factors
Revenue collapsed to zero
A zero-revenue latest period indicates that the business has not yet established dependable commercial sales, while negative gross profit compounds the weakness. This leaves future funding and value creation heavily dependent on clinical progress and eventual product launch execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Anti-infective pipeline targets resistant pathogens
Targeting drug-resistant bacterial infections addresses a substantial unmet medical need and gives the pipeline a clear clinical rationale. If development succeeds, these candidates could serve indications where existing antibiotics are less effective, supporting differentiated commercial potential over the next several years.
Read all positive factors
Recce Pharmaceuticals Ltd. (RCE) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$96.32M
Dividend YieldN/A
Average Volume (3M)84.14K
Price to Earnings (P/E)―
Beta (1Y)1.34
Revenue GrowthN/A
EPS Growth42.51%
CountryAU
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.05
Shares Outstanding305,770,080
10 Day Avg. Volume62,163
30 Day Avg. Volume84,136
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)-7.00
Price to Sales (P/S)0.00
P/FCF Ratio-11.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.09
Revenue Forecast (FY)AU$8.85M
Recce Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating on the research, advancement, and market introduction of synthetic anti-infective treatments across Australia, the United States, and the United Kingdom. The company's...
Recce Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
24
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 7.51M | 5.03M | 4.37M | 3.08M |
| Gross Profit | -356.40K | -2.94M | -2.19M | 4.15M | 2.90M |
| EBITDA | -22.81M | -20.33M | -21.35M | -16.99M | -13.87M |
| Net Income | -14.96M | -21.43M | -17.66M | -13.08M | -10.99M |
Balance Sheet | |||||
| Total Assets | 8.53M | 12.41M | 6.37M | 2.56M | 12.62M |
| Cash, Cash Equivalents and Short-Term Investments | 2.69M | 10.45M | 4.42M | 1.56M | 11.58M |
| Total Debt | 10.44M | 10.77M | 811.19K | 250.57K | 74.76K |
| Total Liabilities | 25.25M | 15.47M | 15.89M | 5.14M | 2.56M |
| Stockholders Equity | -16.72M | -3.05M | -9.52M | -2.59M | 10.06M |
Cash Flow | |||||
| Free Cash Flow | -9.95M | -20.47M | -13.15M | -12.73M | -9.05M |
| Operating Cash Flow | -9.89M | -20.44M | -13.01M | -12.69M | -9.01M |
| Investing Cash Flow | 123.60K | -443.90K | -141.90K | -38.63K | -40.34K |
| Financing Cash Flow | 2.01M | 26.92M | 16.00M | 2.71M | -240.50K |
Recce Pharmaceuticals Ltd. Technical Analysis
Negative
0.38
Price Trends
0.36
Negative
0.41
Negative
0.48
Negative
Market Momentum
-0.01
Positive
34.16
Neutral
26.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RCE, the sentiment is Negative. The current price of 0.38 is above the 20-day moving average (MA) of 0.34, above the 50-day MA of 0.36, and below the 200-day MA of 0.48, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 34.16 is Neutral, neither overbought nor oversold. The STOCH value of 26.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:RCE.
Recce Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | AU$91.41M | 24.84 | 46.74% | ― | 29.68% | 1520.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$415.04M | -46.49 | -42.35% | ― | 145.32% | 25.75% | |
48 Neutral | AU$12.91M | -3.10 | -31.88% | ― | 5.85% | 45.13% | |
43 Neutral | AU$49.71M | -0.59 | -118.74% | ― | 499.47% | 31.20% | |
43 Neutral | AU$96.32M | -5.98 | 84.67% | ― | ― | 42.51% | |
43 Neutral | AU$5.57M | -3.56 | -54.03% | ― | ― | -100.00% |
* Healthcare Sector Average
AU:RCE
Recce Pharmaceuticals Ltd.
0.31
-0.13
-29.86%
AU:BIT
Biotron
―
―
―
AU:SPL
Starpharma Holdings Limited
0.80
0.46
140.18%
AU:IMC
Immuron Limited
0.04
-0.05
-56.52%
AU:BOT
Botanix Pharmaceuticals Limited
0.02
-0.15
-88.48%
AU:BIO
Biome Australia Ltd
0.40
-0.08
-17.53%
Recce Pharmaceuticals Ltd. Corporate Events
Recce Pharmaceuticals Reports Lapse of Conditional Options
Oct 1, 2026
Recce Pharmaceuticals has notified the market of the cessation of 114,999 RCEAO options, which were due to expire on 07 November 2029 at an exercise price of $0.56. The options have lapsed following the failure or impossibility of satisfying the c...
Recce Pharmaceuticals faces shareholder push for governance changes and board shake-up
Sep 29, 2026
Recce Pharmaceuticals has received a shareholder notice under Australian corporations law proposing governance changes and an independent review of its strategy. The notice, submitted by substantial shareholder Gavin Brown, seeks to amend the comp...
Recce Sets 2026 AGM Date as It Advances Synthetic Anti-Infective Pipeline
Sep 18, 2026
Recce Pharmaceuticals has scheduled its 2026 Annual General Meeting for 6 November 2026 in Sydney and set 25 September 2026 as the deadline for director nominations, signaling ongoing corporate governance processes and board planning. The meeting ...
Recce Investors Reject Option Issues and Placement Ratification at General Meeting
Sep 2, 2026
Recce Pharmaceuticals reported the results of its general meeting in Sydney, where all resolutions were conducted by poll and several key proposals failed to secure shareholder approval. The most significant rejection concerned the proposed issue ...
Recce Pharmaceuticals Issues Investor Presentation with Extensive Legal Disclaimers
Sep 2, 2026
Recce Pharmaceuticals has released a general meeting presentation that emphasises extensive legal and investment disclaimers, cautioning prospective investors not to treat its materials as financial, legal or tax advice and to undertake their own ...
Recce Pharmaceuticals Files ASX Corporate Governance Statement and Appendix 4G
Aug 31, 2026
Recce Pharmaceuticals has lodged its corporate governance statement for the year ended 30 June 2026 as part of its annual report, confirming compliance with ASX Listing Rule requirements. The statement, current as at 31 August 2026 and approved by...
Recce Pharmaceuticals Narrows Loss as Global Anti-Infective Programs Advance
Aug 31, 2026
Recce Pharmaceuticals reported a narrower net loss for the year to 30 June 2026, reflecting continued investment in its anti-infective portfolio while remaining pre-revenue. The company advanced its lead candidate R327G into patient dosing in a re...
Recce wins Australian approval to expand pivotal Phase 3 diabetic foot trial
Aug 19, 2026
Recce Pharmaceuticals has secured approval from an Australian Human Research Ethics Committee for a key amendment to its pivotal Phase 3 trial of RECCE 327 Topical Gel in diabetic foot infections. The change adds a randomized, active-controlled, n...
Recce Director Lifts Stake via Share Purchase Plan
Aug 6, 2026
Recce Pharmaceuticals disclosed a change in director Dr John Prendergast’s holdings following his participation in the company’s recent share purchase plan. Prendergast acquired 37,500 fully paid ordinary shares at $0.40 each, increasi...
Recce Pharmaceuticals Issues 250,000 New Shares Under Corporations Act Exemption
Aug 4, 2026
Recce Pharmaceuticals has issued 250,000 fully paid ordinary shares on 31 July 2026 and notified the market that this capital raising was conducted without a prospectus under the exemption provisions of the Corporations Act. The company confirmed ...
Recce Pharmaceuticals Seeks ASX Quotation for Advisory Fee Shares
Aug 2, 2026
Recce Pharmaceuticals Ltd., an Australian biotech company listed on the ASX as RCE, operates in the pharmaceutical and life sciences sector. It develops medical therapies and uses a mix of cash and equity-based compensation to engage corporate adv...
Recce Raises A$6.4m via Placement and Share Purchase Plan, Adds Layered Option Incentives
Jul 31, 2026
Recce Pharmaceuticals has completed its Share Purchase Plan, raising approximately A$2.4 million from shareholders, alongside a previously completed A$4.0 million institutional placement. The combined Offer has delivered total proceeds of A$6.4 mi...
Recce Pharmaceuticals Seeks ASX Quotation for Over 6 Million New Shares
Jul 31, 2026
Recce Pharmaceuticals Ltd has applied for quotation of 6,051,250 new ordinary fully paid shares on the ASX, designated under the code RCE, with an issue date of 31 July 2026. The securities are being brought to market through a standard Appendix 2...
Recce Pharmaceuticals Calls September Virtual General Meeting for Shareholders
Jul 30, 2026
Recce Pharmaceuticals has called a virtual General Meeting for shareholders to be held at 10:00 A.M. AEST on 2 September 2026, and has begun dispatching the formal Notice of Meeting, proxy forms and access letters. The board-approved convening of ...
Recce Positioned as U.S. Unveils US$66.9 Billion Antimicrobial Biodefense Plan
Jul 30, 2026
The U.S. Administration for Strategic Preparedness and Response has unveiled a five‑year, US$66.9 billion medical countermeasures funding plan targeting pandemics, antimicrobial resistance and other health emergency threats. Broad‑spec...
Recce Wins Key Vietnamese Patent for Novel Anti-Infectives
Jul 13, 2026
Recce Pharmaceuticals has secured a Vietnamese patent for its Family 4 anti-infectives, covering the preparation, use and multiple delivery methods of RECCE 327 and RECCE 529 in treating a wide range of bacterial and viral infections. The grant ex...
Recce Pharmaceuticals Opens $4m Share Purchase Plan to Fund Anti-Infective Pipeline
Jul 5, 2026
Recce Pharmaceuticals has opened its previously announced share purchase plan, offering eligible shareholders in Australia, New Zealand and certain accredited investors in the United States the opportunity to subscribe for new fully paid ordinary ...
Recce Pharmaceuticals Completes Share Placement and Issues Cleansing Notice
Jul 3, 2026
Recce Pharmaceuticals has completed the remaining tranche of a previously announced share placement, issuing 150,000 fully paid ordinary shares at $0.40 each to sophisticated investors. This final allotment closes the capital raising flagged to th...
Recce Pharmaceuticals Seeks Quotation for 150,000 New ASX Shares
Jul 3, 2026
Recce Pharmaceuticals Ltd has applied for quotation of 150,000 new ordinary fully paid shares on the Australian Securities Exchange, with an issue date of 3 July 2026. The additional securities, issued under a previously announced transaction, wil...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.